newsfilter
← Latest News
Business Wire·

Baxalta to Showcase Innovation Leadership in Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, will present data highlighting its commitment to innovation in primary immunodeficiencies (PI) at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, March 4 – 7, 2016 in Los Angeles, California.